Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

698.13 +4.63 (+0.67%)
Streaming Delayed Price Updated: 9:47 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
57 58 Next >
News headline image
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys? ↗
There's room for multiple winners in the fast-growing weight-loss market. 
Via The Motley Fool
News headline image
The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition ↗
Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today ↗
 
Via Benzinga
News headline image
Earnings Outlook For Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast ↗
4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70. 
Via Benzinga
News headline image
Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Stock-Split Watch: Could These 2 Market-Beaters Be Next? ↗
Investors might continue bidding up shares of these companies regardless. 
Via The Motley Fool
News headline image
Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today? ↗
4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity. 
Via Benzinga
News headline image
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
News headline image
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? ↗
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. 
Via Benzinga
News headline image
The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High ↗
Shares usually rally on Eylea news, but Regeneron stock is on the rise following fourth-quarter beats from two other products. 
Via Investor's Business Daily
News headline image
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year ↗
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. 
Via Benzinga
News headline image
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 2, 2024 ↗
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion. 
Via Benzinga
News headline image
3 Top Pharma Stocks to Buy Now: February 2024 ↗
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth. 
Via InvestorPlace
News headline image
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't. ↗
The company missed total sales and earnings expectations. 
Via Investor's Business Daily
News headline image
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
AI, Biotech, Energy Sectors Expect M&A Revival For 2024 ↗
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
News headline image
3 Magnificent Stocks to Buy and Hold Forever ↗
Many investors will want to consider owning these stocks for a long time. 
Via The Motley Fool
News headline image
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation ↗
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients. 
Via Benzinga
News headline image
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts ↗
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy. 
Via Benzinga
News headline image
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.